Figure 3.

Global, inducible deletion of Ptpn6 leads to features of the motheaten phenotype. (A) Body weight of mice of the indicated genotypes, given as % of initial mouse weight, measured over time following treatment with 200 mg/kg tamoxifen bid for 4 days (shaded area). Data is from n = 9–10 mice per group. (B) Flow cytometric analysis of CD11b⁺ cells in peripheral blood taken 14 days after initial tamoxifen dose, data shown as % of live CD45⁺ cells. (C) Spleen weight relative to mouse body weight (left), and flow cytometric analysis of CD11b⁺ splenocytes (right) measured 50 days after initial tamoxifen dose. (D,E) total number of bronchoalveolar lavage (BAL) cells from mice of the indicated genotypes measured at either day 14 (2 wks) and 28 (4 wks) following 200 mg/kg tamoxifen bid for 4 days (D), or day 50 following 5 days of 200 mg/kg/day (low dose) or 4 days of 200 mg/kg bid (high dose) (E). (F) Flow cytometric analysis of BAL cells at day 28 after initial tamoxifen dose of 200 mg/kg tamoxifen bid for 4 days. Data is graphed as % of CD45⁺ live cells. (G) Representative H&E and anti-F4/80-stained sections of lung lobes from mice of the indicated genotypes. H&E stained sections were from lungs harvested 4 weeks after initial tamoxifen dose of 200 mg/kg tamoxifen bid for 4 days, two independent experiments with 4–7 mice/group. Anti-F4/80 staining is from one experiment with 5 mice/group; lungs were collected day 27 after tumor implantation. Error bars represent SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.